At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 246 enrolled
Drug / intervention
Pegcetacoplan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients With Geographic Atrophy (GA)
In Brief
A Phase 2 clinical trial evaluating Pegcetacoplan and Sham Procedure for Geographic Atrophy. Completed, enrolled 246 participants across 46 sites in 3 countries.
Detailed Summary
The primary objectives of the study are to assess the safety, tolerability and evidence of activity of multiple intravitreal (IVT) injections of pegcetacoplan in subjects with Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeographic Atrophy
CountriesAustralia, New Zealand, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartSep 2015
Primary CompletionJul 2017
Study CompletionJan 2018
TodayJul 2026
First PostedJul 20, 2015
Enrollment StartSep 24, 2015
Primary CompletionJul 14, 2017
Study CompletionJan 17, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.0 years ago
Interventions
Pegcetacoplandrug
Sham Procedureother